Anzeige
Meldung des Tages: Der Vorteil des Meeresbodens: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

Elanco Animal Health News

Aktie
WKN:  A2N6BH ISIN:  US28414H1032 US-Symbol:  ELAN Branche:  Pharmazeutika Land:  USA
23,68 $
+0,55 $
+2,38%
20,129 € 17.04.26
Depot/Watchlist
Marktkapitalisierung *
9,49 Mrd. €
Streubesitz
-
KGV
24,08
Index-Zuordnung
-

Elanco Animal Health News

16.04.26 - PR Newswire
Elanco Confirms Date and Conference Call for First Quarter 2026 Financial Results Announcement
Elanco Confirms Date and Conference Call for First Quarter 2026 Financial Results Announcement PR Newswire
09.04.26 - PR Newswire
Elanco Launches Advantage™ Collar for Dogs with Four Months of Continuous Protection from Fleas, Ticks and Mosquitoes*
Elanco Launches Advantage™ Collar for Dogs with Four Months of Continuous Protection from Fleas, Ticks and Mosquitoes* PR Newswire
03.04.26 Spiegel.de
Eli Lilly profitiert von neuer Abnehmpille Foundayo
Die US-​Arzneimittelbehörde FDA hat die Diätpille Foundayo zugelassen. Aktien des Herstellerkonzerns Eli Lilly gewannen daraufhin an der Börse kräftig an Wert. Hier klicken, um ...
24.02.26 - PR Newswire
Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results
Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results PR Newswire
19.02.26 - PR Newswire
Elanco to Participate in Upcoming Investor Conferences
Elanco to Participate in Upcoming Investor Conferences PR Newswire
13.02.26 - PR Newswire
Elanco Announces Updates to Board of Directors
Elanco Announces Updates to Board of Directors PR Newswire
22.01.26 - PR Newswire
Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement
Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement PR Newswire
06.01.26 - PR Newswire
Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference PR Newswire
31.12.25 - PR Newswire
Elanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis
Elanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis PR Newswire
18.12.25 - PR Newswire
Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs
Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm ...
09.12.25 - PR Newswire
Elanco Investor Day Defines New Era as Sustainable Growth Company
Elanco Investor Day Defines New Era as Sustainable Growth Company PR Newswire
21.11.25 - PR Newswire
Elanco's Credelio™ CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats
Elanco's Credelio™ CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats PR Newswire
20.11.25 - PR Newswire
Elanco to Participate in the Upcoming Investor Conferences
Elanco to Participate in the Upcoming Investor Conferences PR Newswire
13.11.25 - PR Newswire
Alloy Partners Launches OneHealth Studio to Create Startups at the Convergence of Animal, Plant and Human Health
Alloy Partners Launches OneHealth Studio to Create Startups at the Convergence of Animal, Plant and Human Health PR Newswire
05.11.25 - PR Newswire
Elanco Animal Health Reports Third Quarter 2025 Results
Elanco Animal Health Reports Third Quarter 2025 Results PR Newswire
27.10.25 - PR Newswire
Elanco Announces Expansion of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio™ (lotilaner) Labels, Offering Protection Against Lyme Disease and an Emerging Tick Species
Elanco Announces Expansion of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio™ (lotilaner) Labels, Offering Protection Against ...
24.10.25 - PR Newswire
Elanco's Credelio™ (lotilaner) Receives First Ever FDA Emergency Use Authorization (EUA) against New World Screwworm (NWS) in Dogs
Elanco's Credelio™ (lotilaner) Receives First Ever FDA Emergency Use Authorization (EUA) against New World Screwworm (NWS) in Dogs PR Newswire
16.10.25 - PR Newswire
Elanco to Host Investor Day on December 9
Elanco to Host Investor Day on December 9 PR Newswire
08.10.25 wallstreetONLINE Redaktion
Noch nicht am Limit: Diese Tiermedizin-Aktie bleibt ein Top-Pick trotz 70 Prozent Kursplus
Trotz eines Kursanstiegs von 70 Prozent in diesem Jahr bleibt Elanco Animal Health laut JPMorgan ein attraktives Investment. Kursziel weiter angehoben.Die Aktie von Elanco ...
01.10.25 - PR Newswire
Elanco Confirms Date and Conference Call for Third Quarter 2025 Financial Results Announcement
Elanco Confirms Date and Conference Call for Third Quarter 2025 Financial Results Announcement PR Newswire

Newssuche

Videos

newspaper
16.04.26 +2,80%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »